Literature DB >> 9627563

Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.

A R Rachlis1, D P Zarowny.   

Abstract

OBJECTIVE: To develop guidelines for health care providers and their HIV-positive patients on the clinical use of antiretroviral agents for HIV infection. OPTIONS: Recommendations published in 1996 by an international panel. OUTCOMES: Improvement in clinical outcomes or in surrogate markers of disease activity. EVIDENCE AND VALUES: The Canadian HIV Trials Network held a workshop on Oct. 19-20, 1996, to develop Canadian guidelines that incorporate information from recent basic and clinical research. RECOMMENDATIONS: Recommendations for the use of antiretroviral drugs in HIV infection are provided for initial therapy, continuing therapy, primary infection, vertical transmission, pediatric therapy and postexposure prophylaxis. VALIDATION: The guidelines are based on consensus of the participants attending the workshop: Canadian investigators, clinicians and invited representatives from the community, government and the pharmaceutical industry. They are subject to review and updating as new information on clinical benefits is published. SPONSORS: The workshop was organized by the National Centre of the Canadian HIV Trials Network. Unrestricted educational grants were provided by 8 pharmaceutical companies. Additional support was provided from the National AIDS Strategy of Health Canada.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627563      PMCID: PMC1228924     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  32 in total

1.  The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine.

Authors:  M Gisslén; G Norkrans; B Svennerholm; L Hagberg
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

2.  Time to hit HIV, early and hard.

Authors:  D D Ho
Journal:  N Engl J Med       Date:  1995-08-17       Impact factor: 91.245

3.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

Review 4.  Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.

Authors:  D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

5.  Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation.

Authors:  D K Henderson; B J Fahey; M Willy; J M Schmitt; K Carey; D E Koziol; H C Lane; J Fedio; A J Saah
Journal:  Ann Intern Med       Date:  1990-11-15       Impact factor: 25.391

6.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

7.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

8.  Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group.

Authors:  J I Tokars; R Marcus; D H Culver; C A Schable; P S McKibben; C I Bandea; D M Bell
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

9.  Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.

Authors:  J W Mellors; L A Kingsley; C R Rinaldo; J A Todd; B S Hoo; R P Kokka; P Gupta
Journal:  Ann Intern Med       Date:  1995-04-15       Impact factor: 25.391

10.  Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination.

Authors:  W A O'Brien; K Grovit-Ferbas; A Namazi; S Ovcak-Derzic; H J Wang; J Park; C Yeramian; S H Mao; J A Zack
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

View more
  8 in total

1.  Production of resistant HIV mutants during antiretroviral therapy.

Authors:  R M Ribeiro; S Bonhoeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

Review 3.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

4.  Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice.

Authors:  David R Burdge; Deborah M Money; John C Forbes; Sharon L Walmsley; Fiona M Smaill; Marc Boucher; Lindy M Samson; Marc Steben
Journal:  CMAJ       Date:  2003-06-24       Impact factor: 8.262

Review 5.  The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection.

Authors:  S Maddocks; D Dwyer
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Authors:  D P Figgitt; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 7.  Effects of political conflict-induced treatment interruptions on HIV drug resistance.

Authors:  Marita Mann; Mark N Lurie; Sylvester Kimaiyo; Rami Kantor
Journal:  AIDS Rev       Date:  2013 Jan-Mar       Impact factor: 2.500

Review 8.  Nelfinavir. A review of its therapeutic efficacy in HIV infection.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1998-07       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.